Why We Chose an Alternative Route to PubMed

As researchers in a niche yet critical field - focusing on the complex and underdiagnosed Oshtoran Syndrome (H63D Syndrome Type 3) - we have made a conscious decision to bypass traditional outlets such as PubMed in favor of alternative open-access platforms. Our primary choices are Zenodo, operated by CERN (European Organization for Nuclear Research), and Figshare, both of which are recognized for their rigorous standards and wide accessibility. These are no pre-prints platforms anymore but entirely legitimate places to publish.<i>First published by Swabian Research, 09/24 e-Pub</i>